Helius Medical Technologies 将来の成長

Future 基準チェック /26

Helius Medical Technologiesの収益は年間19.7%で減少すると予測されていますが、年間収益は年間28.6%で増加すると予想されています。EPS は年間36.8%で増加すると予想されています。

主要情報

-19.7%

収益成長率

36.8%

EPS成長率

Medical Equipment 収益成長	17.0%
収益成長率	28.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Recent updates

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Aug 23

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Aug 05

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Aug 18

業績と収益の成長予測

NasdaqCM:HSDT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1	-15	N/A	N/A	1
12/31/2025	1	-14	N/A	N/A	1
12/31/2024	0	-11	N/A	N/A	1
9/30/2024	1	-9	-11	-11	N/A
6/30/2024	1	-9	-10	-10	N/A
3/31/2024	1	-9	-10	-10	N/A
12/31/2023	1	-9	-10	-10	N/A
9/30/2023	1	-13	-11	-11	N/A
6/30/2023	1	-10	-12	-12	N/A
3/31/2023	1	-12	-13	-13	N/A
12/31/2022	1	-14	-14	-14	N/A
9/30/2022	1	-13	-16	-16	N/A
6/30/2022	1	-17	-15	-15	N/A
3/31/2022	1	-19	-15	-15	N/A
12/31/2021	1	-18	-13	-13	N/A
9/30/2021	0	-17	-12	-12	N/A
6/30/2021	0	-15	-12	-11	N/A
3/31/2021	1	-13	-11	-11	N/A
12/31/2020	1	-14	-12	-12	N/A
9/30/2020	1	-17	-14	-14	N/A
6/30/2020	1	-19	-17	-17	N/A
3/31/2020	1	-16	-18	-18	N/A
12/31/2019	1	-10	-21	-21	N/A
9/30/2019	2	-10	-22	-22	N/A
6/30/2019	2	-8	-20	-20	N/A
3/31/2019	1	-26	-22	-22	N/A
12/31/2018	0	-29	-20	-20	N/A
9/30/2018	N/A	-27	-20	-20	N/A
6/30/2018	N/A	-36	N/A	-21	N/A
3/31/2018	N/A	-24	N/A	-21	N/A
12/31/2017	N/A	-28	N/A	-19	N/A
9/30/2017	N/A	-30	N/A	-18	N/A
6/30/2017	N/A	-20	N/A	-15	N/A
3/31/2017	N/A	-18	N/A	-11	N/A
12/31/2016	N/A	-16	N/A	-10	N/A
9/30/2016	N/A	-12	N/A	-9	N/A
6/30/2016	N/A	-7	N/A	-8	N/A
3/31/2016	N/A	-7	N/A	-8	N/A
12/31/2015	N/A	-5	N/A	-8	N/A
9/30/2015	N/A	-5	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-8	N/A
3/31/2015	N/A	-10	N/A	-6	N/A
12/31/2014	N/A	-8	N/A	-5	N/A
9/30/2014	N/A	-6	N/A	-3	N/A
6/30/2014	N/A	-3	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HSDT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: HSDT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: HSDT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: HSDTの収益 ( 28.6% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: HSDTの収益 ( 28.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HSDTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Helius Medical Technologies 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Recent updates

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022

Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange

Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020)

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Consensus revenue estimates fall to US$333.0k

Helius Medical makes CEO, CFO appointments

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time

Full year 2020 earnings released: US$11.80 loss per share (vs US$12.99 loss in FY 2019)

Revenue and earnings beat expectations

Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million.

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

Helius Medical Technologies announces reverse stock split

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.077 loss per share

Helius Medical Technologies EPS beats by $0.01, beats on revenue

Helius Medical Technologies, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Helius Medical Technologies, Inc. announced that it has received $3.44419 million in funding from Maple Leaf Investments and other investors

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights

Helius Medical Technologies, Inc. Announces CEO Changes

Helius Medical Technologies, Inc. Unable to Estimate the Duration and Impact of the COVID-19 Pandemic on its Financial and Operating Results for the Full Year 2020

Earnings released

Helius Medical Technologies, Inc. to Report Q2, 2020 Results on Aug 12, 2020

業績と収益の成長予測